Travere Therapeutics Director Sells $328,560 in Stock

Insider trading activity raises concerns about short-term outlook for the biotech firm.

Apr. 16, 2026 at 9:26pm

Got story updates? Submit your updates here. ›

A dramatic, high-contrast close-up of the inner workings of a financial instrument, such as the gears and circuits of a stock ticker or banking computer system, representing the complex infrastructure that powers the financial markets.Insider trading activity at Travere Therapeutics highlights the complex machinery behind the biotech firm's recent stock market gains.San Diego Today

Travere Therapeutics director Gary Lyons sold 8,000 shares of the company's stock for a total value of $328,560. The transaction represented a 12.21% decrease in Lyons' ownership stake in the biopharmaceutical firm, which is focused on rare kidney and genetic disorders.

Why it matters

Significant insider selling, including by the CEO, CFO and other executives, can fuel investor concerns about the near-term outlook for a stock, even if the trades are pre-planned or for tax purposes. This activity may raise caution about Travere's recent stock run-up and the sustainability of its recent gains.

The details

Lyons' stock sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, the director still owns 57,500 shares in Travere Therapeutics, valued at approximately $2.36 million. The company's stock price has risen sharply in recent months on positive news, including the FDA's full approval of its drug Filspari for a rare kidney disorder.

  • The stock sale occurred on Tuesday, April 14, 2026.
  • Travere Therapeutics' stock price closed at $39.54 on Thursday, April 16, 2026.

The players

Gary Lyons

A director at Travere Therapeutics who sold 8,000 shares of the company's stock.

Travere Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California, that is dedicated to developing therapies for rare kidney and genetic disorders.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Travere Therapeutics' upcoming earnings report and any further commentary from management about the commercial launch of Filspari and the company's growth prospects.

The takeaway

The insider selling activity at Travere Therapeutics raises short-term concerns about the stock's valuation and momentum, even as the company's lead drug secures regulatory approval and expands its addressable market. Investors will need to weigh the positive long-term potential against the potential for near-term volatility.